Dear Researchers,

The library will operate on a duty schedule between 22 December 2025 and 4 January 2026. During this period, it will be possible to upload publications, but all other services will be suspended.

Thank you for your understanding.

Baráth Barbara

Publication list

Tudóstér co-authors statistics filterable publication list

Export to RIS (EndNote, Mendeley, RefWorks, Zotero etc.)

Upload publications

Request certified publication list

Uploaded publications:

Publications in DEA:

OA:

Date range:

2018-2023

2023

Somodi, L., Horváth, E., Bárdos, H., Baráth, B., Pethő, D., Katona, É., Balla, J., Mutch, N. J., Muszbek, L.: Cellular FXIII in Human Macrophage-Derived Foam Cells.
Int. J. Mol. Sci. 24 (5), 1-12, (article identifier: 4802), 2023.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis

Q1 Computer Science Applications

D1 Inorganic Chemistry

Q1 Medicine (miscellaneous)

Q2 Molecular Biology

D1 Organic Chemistry

Q1 Physical and Theoretical Chemistry

D1 Spectroscopy

2022

Székely, E. G., Orbán-Kálmándi, R. A., Szegedi, I., Katona, É., Baráth, B., Czuriga-Kovács, K. R., Lóczi, L., Molnárné Vasas, N., Fekete, I., Fekete, K., Berényi, E., Oláh, L., Csiba, L., Bagoly, Z.: Low [alfa]2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis.
Front. Cardiovasc. Med. 9, 1-14, (article identifier: 901286), 2022.

doi DEA WoS Scopus

Journal metrics:

Q1 Cardiology and Cardiovascular Medicine

2021

Baráth, B., Kissné Bogáti, R., Miklós, T., Kállai, J., Mezei, Z. A., Bereczky, Z., Muszbek, L., Katona, É.: Effect of [alfa]2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Thromb. Res. 203, 110-116, 2021.

doi DEA WoS Scopus

Journal metrics:

Q1 Hematology

Bagoly, Z., Baráth, B., Orbán-Kálmándi, R. A., Szegedi, I., Kissné Bogáti, R., Sarkady, F., Csiba, L., Katona, É.: Incorporation of [alfa]2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Biomolecules. 11 (3), 1-13, (article identifier: 347), 2021.

doi DEA WoS Scopus

Journal metrics:

Q2 Biochemistry

Q2 Molecular Biology

2020

Ząbczyk, M., Natorska, J., Bagoly, Z., Sarkady, F., Baráth, B., Katona, É., Bryk, A. H., Zettl, K., Wisniewski, J. R., Undas, A.: Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
J. Physiol. Pharmacol. 71 (4), 519-524, 2020.

doi DEA

Journal metrics:

Q2 Medicine (miscellaneous)

Q2 Pharmacology

Q2 Physiology

Bryk, A. H., Siudut, J., Broniatowska, E., Bagoly, Z., Baráth, B., Katona, É., Undas, A.: Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Thromb. Res. 185, 88-62, 2020.

doi DEA WoS Scopus

Journal metrics:

Q1 Hematology

2018

Baráth, B., Bagoly, Z., Szegedi, I., Orbán-Kálmándi, R. A., Csiba, L., Katona, É.: Incorporation of Alpha-2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients Receiving Thrombolytic Therapy.
Proceedings. 2 (9), 101-102, 2018.

doi DEA

Bagoly, Z., Baráth, B., Szegedi, I., Orbán-Kálmándi, R. A., Csiba, L., Katona, É.: The Effect of Factor XIII Levels on the Incorporation of [alfa]2-plasmin Inhibitor into Fibrin Clots: association with the Therapeutic Outcome of Acute Ischemic Stroke Patients.
Res. Pract. Thromb. Haemost. 2, 198, 2018.

doi DEA